|
Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs). |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda |
Research Funding - EMD Serono (Inst); Merck (Inst) |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche |
Expert Testimony - Oryzon Genomics |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
Research Funding - Merck Serono |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Roche |
|
|
No Relationships to Disclose |
|
|
Other Relationship - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Pfizer; Roche |
Consulting or Advisory Role - Abbvie; Roche |
Travel, Accommodations, Expenses - AstraZeneca; MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Novartis; Roche |
Speakers' Bureau - Amgen; Ipsen; MSD Oncology; Roche; Sanofi; Symphogen |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |